Moderna to take mRNA flu and HIV vaccines into Phase 1 trials this year
By Rachel Arthur contact
15-Apr-2021 - Last updated on 28-Apr-2021 at 07:58 GMT
As part of its Vaccine Day this week, the company has updated its vaccine development timelineĀ and unveiled results from early stage mRNA vaccine trials.
mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs). It is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF). A Phase 1 study for the candidate will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing.
A second approach, mRNA-1574, is being evaluated with the US National Institutes of Health (NIH) and includes multiple native-like trimer antigens.
Leave a Comment
Related Posts
Worse Than The Disease? Reviewing Some Possible Unintended Consequences of The mRNA Vaccines Against COVID-19
Comment
Tale of Two Intersecting Epidemics: Why We Need mRNA Vaccines in Africa, and For All Who Are Immunocompromised
Comment
Recent Posts
By-Product Valorization as a Means for the Brewing Industry to Move toward a Circular Bioeconomy
Comment
'The party is over for developers looking for AI freebies' — Google terminates Gemini API free access within months amidst rumors that it could charge for AI search queries
Comment
